


From: Tracey Hernandez/Morristown/Watson
Sent: Tuesday, October 16, 2007 1:11 PM
To: Michael Cochrane
Subject: Re: Fw: Distributor Notification

Michael-

Did you guys cut them off as a result of receiving Kyle's email? If so, what are we missing to not have picked them up prior (not being critical, I realize some of this ends up being more of a guess....just trying to see if there is anything else we need to add to our SOM program)?

 Michael Cochrane/Anda/Anda/Andrx@ANDRX

Michael
Cochrane/Anda/Anda/Andrx@ANDRX To Tracey
Hernandez/Morristown/Watson@WATSON
10/16/2007 09:03 AM
cc
Subject
Re: Fw: Distributor Notification 

All of them were customers at one point with Anda. The ones that are listed below were cut off yesterday. The ones that are not listed below were cut off before Kyle's email.

Thanks
Mike

308828 MEDRITE PHARMACY
306932 CARDOZO-ISAZA, ERNESTO MD
161444 GIDDENS, LEE J. MD
84216 KIJNER, HERRY H MD
68948 KRONENBERG, ROBERT DM
101646 WASSERMAN, H NORMAN MD
84412 ZELFMAN, MIKHAIL MD

 Tracey Hernandez/Morristown/Watson@WATSON

Tracey
Hernandez/Morristown/Watson@WATSON To Larry
Shaffer/Morristown/Watson@Watson,
Mary
Moskello/Morristown/Watson@Watson,
Michael
Cochrane/Anda/Anda/Andrx@Andrx
cc Sandra

PLAINTIFFS TRIAL
EXHIBIT
P-03820_00001

Simmons/Morristown/Watson@Watson,
Mary Woods/Corona/Watson@Watson,
Judy
Callahan/Corona/Watson@Watson, Al
Paonessa III/Anda/Andrx@Andrx,
Diane
Miranda/Morristown/Watson@Watson

SubjectFw: Distributor Notification

Larry/Mary/Michael-

Please make sure the entities noted below are not authorized to receive controlled products. Also, please let me know if they are a current customer and/or have received controlled products in the past 24 mos. Thanks!

----- Forwarded by Tracey Hernandez/Morristown/Watson on 10/16/2007 08:51 AM -----

"Wright, Kyle J."
<Kyle.J.Wright@usdoj.gov> To"ODC" <ODC@usdoj.gov>
10/15/2007 04:18 PM cc
SubjectDistributor Notification

A distributor(s), by its (their) own initiative, recently notified the DEA that they have discontinued and/or restricted business with the below listed customer(s). You are once again reminded of your responsibilities to exercise due diligence in accordance with Title 21, C.S.A., Section 823(a)(1) for *the maintenance of effective controls against diversion of controlled substances into other than legitimate medical, scientific, and industrial channels*, and to review your customer's account, (especially new accounts), to ensure that all purchases are only for these reasons. The actions taken by this (these) distributor(s) does not infer these customer(s) were/or are engaged in suspicious activities.

Prime Pharmacy, Houston, TX (BP7046926)
Medrite Pharmacy, Philadelphia, PA (FM0037463)
Satellite Drug & Pharmacy, Newport Richey, FL (BS9225978)
Dr. Ernesto CARDOZO-ISAZA, Pembroke Pines, FL (BC8861278)
Dr. Lee J. GIDDENS, Hollywood, FL (FG0145688)
Dr. Henry H. KIJNER, Hollywood, FL (FK0349072)
Dr. John Lemual COSBY, Pompano Beach, FL (BC6541874)
Dr. Israel RABINSKY, Palm Beach Gardens, FL (BR2721137)
Dr. Robert D. KRONENBERG, Davie, FL (BK5845726)
Dr. Michael J. MILLER, Coconut Creek, FL (BM8577782)
Dr. Jack Alvin NORDEN, Lauderdale Lakes, FL (AN6375908)
Dr. Fredric A. SWARTZ, Pompano Beach, FL (AS9122045)
Dr. Norman WASSERMAN, Hollywood, FL (BW8071855)
Dr. Mikhail ZELFMAN, North Miami, FL (BZ9752379)

Your company has the right to continue sales as deemed appropriate and this notification of itself does not infer administrative or criminal proceedings will be initiated based on this notification alone.

If your company deems it appropriate to terminate or restrict a customer, as a courtesy to the distributor community, please notify this office. You are required in accordance with Title 21, C.F.R., Section 1301.74(b) to report suspicious orders to the DEA.

This communication, along with any attachments, is covered by federal and state law governing electronic communications and may contain confidential and legally privileged information. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, use or copying of this message is strictly prohibited. If you have received this in error, please reply immediately to the sender and delete this message. Thank you.

Kyle J. Wright
Staff Coordinator
Pharmaceutical Investigations Section (OEP)
Drug Enforcement Administration
600 Army Navy Drive
Arlington, VA 22202
(202) 658-7514 - Office
(703) 653-5055 - FAX